Recce Pharmaceuticals completes cohort dosing in R327 Phase I/II trial
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) continues its trajectory in pioneering a new class of Synthetic Antiinfectives, spotlighting its recent achievement. The company announced that Scientia Clinical Research has successfully finalized cohort dosing for both male and female subjects. This is part of the crucial Phase I/II UTI/Urosepsis clinical trial, focusing on evaluating the performance of […]